1. Addressing Unmet Needs in Myelofibrosis

2. Activity Goals

3. The MPN Burden: Treatment Goals

4. Risk Stratification Tools

5. Goals of Therapy: Individualizing Treatment

6. MPN Symptom Burden is Significant, and Worse Than General Population

7. COMFORT II: 5-Year Follow-up Duration of Spleen Response

8. Splenectomy

9. Ruxolitinib

10. Pacritinib-Induced Spleen Volume Reduction

11. Pacritinib vs BAT

12. Pacritinib-Induced Symptom Improvement

13. Pacritinib-Induced RBC Transfusion Independence

14. Momelotonib: JAK1/JAK2 Inhibitor

15. Imetelstat: First-in-Class Telomerase Inhibitor

16. Ruxolitinib Combinations ASH 2015

17. PRM-151 Adaptive Phase 2: Safety Through 36 Weeks

18. Abbreviations

19. Abbreviations (cont)

20. Abbreviations (cont)